Palomar (NASDAQ:PLMR) Announces Quarterly Earnings Results

Palomar (NASDAQ:PLMR) announced its quarterly earnings results on Tuesday. The company reported $2.36 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.17, FiscalAI reports. Palomar had a net margin of 20.11% and a return on equity of 22.62%. The business had revenue of $314.42 million during the quarter, compared to analysts’ expectations of $621.52 million.

Palomar Stock Down 0.3%

Shares of PLMR traded down $0.40 during mid-day trading on Tuesday, hitting $136.11. 171,252 shares of the company’s stock were exchanged, compared to its average volume of 270,372. The company has a market cap of $3.61 billion, a price-to-earnings ratio of 18.96 and a beta of 0.40. Palomar has a fifty-two week low of $100.81 and a fifty-two week high of $147.62. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.49 and a current ratio of 0.49. The stock’s 50-day moving average is $124.76 and its 200-day moving average is $123.54.

More Palomar News

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Palomar reported second-quarter adjusted earnings of $2.36 per share, beating analysts’ $2.19 estimate by $0.17. The company also posted a 22.62% return on equity and a 20.11% net margin, supporting the investment case based on strong profitability. Palomar Holdings, Inc. Reports Second Quarter 2026 Results
• Neutral Sentiment: Palomar’s chief operating officer, Rodolphe Herve, sold 1,207 shares valued at approximately $163,000. The filing said the sale was intended to cover tax-withholding obligations tied to vested equity awards, reducing the likelihood that it signals a negative view of the company. SEC Insider Transaction Filing
• Negative Sentiment: Quarterly revenue was $314.42 million, substantially below the approximately $621.5 million analyst estimate. This major top-line shortfall may offset the EPS beat and raise questions about revenue trends or the comparability of the reported figures. Palomar Q2 Earnings Snapshot
• Negative Sentiment: Zacks Research lowered its FY2028 EPS forecast to $10.45 from $10.62 and maintained a “Hold” rating. Although the estimate reduction is modest, it adds to concerns about longer-term earnings growth. Palomar Analyst Estimate Report

Insider Buying and Selling at Palomar

In other Palomar news, insider Timothy Carter sold 480 shares of the stock in a transaction that occurred on Sunday, June 28th. The shares were sold at an average price of $124.29, for a total transaction of $59,659.20. Following the sale, the insider directly owned 1,670 shares in the company, valued at $207,564.30. This represents a 22.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Mac Armstrong sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $112.96, for a total transaction of $395,360.00. Following the completion of the transaction, the chief executive officer directly owned 329,388 shares of the company’s stock, valued at $37,207,668.48. This represents a 1.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 22,050 shares of company stock worth $2,875,050. 3.70% of the stock is currently owned by company insiders.

Institutional Trading of Palomar

Several hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in Palomar during the 4th quarter worth $33,000. NewEdge Advisors LLC acquired a new stake in Palomar in the 1st quarter valued at about $66,000. Advisory Services Network LLC acquired a new stake in Palomar in the 3rd quarter valued at about $57,000. Smartleaf Asset Management LLC boosted its stake in shares of Palomar by 25.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 672 shares of the company’s stock valued at $91,000 after buying an additional 137 shares during the period. Finally, iSAM Funds UK Ltd purchased a new position in shares of Palomar in the 3rd quarter valued at about $81,000. 90.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PLMR has been the topic of several recent analyst reports. Evercore set a $152.00 price objective on shares of Palomar in a report on Friday, July 10th. Piper Sandler lifted their target price on shares of Palomar from $132.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, July 15th. Keefe, Bruyette & Woods boosted their target price on Palomar from $162.00 to $166.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. Zacks Research cut Palomar from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded Palomar from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 18th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $162.50.

Palomar Company Profile

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.